SCHEDULE: Nantahala Capital Amends Soleno Therapeutics Stake

Nantahala Capital Management and its managing members disclosed a 1.99% passive ownership stake in Soleno Therapeutics Inc. as of June 30, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack reported beneficial ownership of 1,001,350 shares of Soleno Therapeutics Inc. Common Stock.
• This ownership represents 1.99% of the total outstanding shares of the class.
• The reporting persons hold shared voting and shared dispositive power over all 1,001,350 shares.
• The filing is an Amendment No. 9 to a Schedule 13G, indicating an update to a previously disclosed passive stake.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of a passive ownership stake by an institutional investor, providing no new information regarding the company's operational or financial performance, thus maintaining a neutral sentiment.

Industry Context

This filing is a routine disclosure of a passive ownership stake by an institutional investor in a biotechnology company. It does not provide specific insights into Soleno Therapeutics Inc.'s operational performance or strategic direction, but rather reflects an investment position.

Stakeholder Impact

• The filing indicates a continued passive investment by Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack, which may be viewed as a vote of confidence by existing shareholders, though the stake is non-controlling.

Key Dates

Keywords

Soleno Therapeutics, Nantahala Capital Management, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, SEC Filing, Biotechnology, Pharmaceuticals